운트바이오

비상장계속사업자

UNDBIO

전용수

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

운트바이오

Business Reg. No. 1278622792 · CEO 전용수

I.Investment Overview

Target운트바이오 (1278622792)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명운트바이오
영문명UNDBIO
대표자전용수
사업자등록번호1278622792
법인등록번호2802110099008
설립일2010.03.16
종업원수21명

V.Workforce

21

Current headcount · 2026.06 as of

VI.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW115.52021103.32022105202392.2202486.22025
영업이익100M KRW-14.32021-18.62022-12.42023-19.4202412.42025
순이익100M KRW-22.92021-222022-17.82023-20.9202417.62025
Item20252024202320222021
자산총계110.7억원97.2억원149.5억원140.7억원153억원
부채총계93.8억원85.7억원120억원111.6억원110.7억원
자본총계16.8억원11.5억원29.5억원29.1억원42.3억원
매출액86.2억원92.2억원105억원103.3억원115.5억원
영업이익12.4억원-19.4억원-12.4억원-18.6억원-14.3억원
순이익17.6억원-20.9억원-17.8억원-22억원-22.9억원

VII.Financial Ratios

FY2025 basis

14.41%

영업이익률

20.4%

순이익률

15.9%

ROA

104.56%

ROE

557.62%

부채비율

15.21%

자기자본비율

VIII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

운트바이오 투심보고서 | Alpha Lenz